<DOC>
	<DOCNO>NCT01305148</DOCNO>
	<brief_summary>The WARFARIN Study clinical trial design determine use genetic information relate warfarin sensitivity help create dose warfarin result less hospitalization death relate warfarin .</brief_summary>
	<brief_title>Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing Therapy INitiation ( WARFARIN )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Men woman least 65 year old 2 . Beginning warfarin ( 0 3 dos warfarin take time enrollment ) variety disease condition require least 30 day oral anticoagulation target INR â‰¥ 2.0 1 . Unable complete study material ( questionnaire ) without assistance ( example , dementia ) 2 . A previous genetically determine warfarin dose 3 . The treating physician agree use recommend warfarin dose feel patient enrol study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>warfarin</keyword>
	<keyword>genetic testing</keyword>
	<keyword>personalize medicine</keyword>
	<keyword>anti-coagulants</keyword>
	<keyword>coumadin</keyword>
</DOC>